Why do most cancer drugs fail clinical trials?

Roughly 95% of oncology drug candidates that show preclinical promise fail to receive FDA approval. The reasons include weak preclinical models, patient heterogeneity, biomarker problems and clinical-trial design issues.

Improving the predictive value of mouse and organoid models, and matching therapies to patient subgroups, is one of the most consequential open questions in drug development.